IP Library Granted Patent US 7,785,801
Granted Patent B2
US 7,785,801 · App. 11/596,106 · Granted Aug 31, 2010

Identification of surface-associated antigens for tumor diagnosis and therapy

Assignee: Ganymed Pharmaceuticals, AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,785,801
App. No.
11/596,106
Granted
Aug 31, 2010
Kind
B2
Abstract

The invention relates to the identification of gene products that are the result of tumor-associated expression and the nucleic acids encoding the same. The invention also relates to the therapy and diagnosis of diseases wherein these gene products are the result of an aberrant tumor-associated expression. The invention also relates to the proteins, polypeptides and peptides that are the result of tumor-associated expression and to the nucleic acids encoding the same.

Claims (4)

1. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 72.

2. A method of diagnosing a cancer of a tissue selected from the group consisting of breast, lung, ear, nose, throat, esophagus, ovary, cervix, skin, prostate, kidney, colon, stomach pancreas, liver, and uterus in a patient, wherein the cancer is characterized by expression of a tumor-associated antigen comprising the polypeptide of SEQ ID NO: 72, which method comprises detecting or quantifying the polypeptide in a sample of the tissue isolated from the patient by contacting the sample with an antibody that selectively binds to the polypeptide.

3. The method of claim 2 , wherein the antibody is conjugated to a diagnostic agent.

4. A method of diagnosing breast cancer in a patient, which method comprises detecting or quantifying a tumor associated antigen comprising a polypeptide of SEQ ID NO: 72 in a breast tissue sample isolated from the patient by contacting the sample with an antibody that selectively binds to the polypeptide.

Assignments (6)
CHANGE OF NAME Recorded Jun 5, 2020
From: BIONTECH AG
To: BIONTECH SE
Reel/Frame 052859/0283 →
CHANGE OF ADDRESS Recorded Nov 21, 2017
From: BIONTECH AG
To: BIONTECH AG
Reel/Frame 044495/0107 →
CHANGE OF NAME Recorded Nov 21, 2017
From: GANYMED PHARMACEUTICALS AG
To: GANYMED PHARMACEUTICALS GMBH
Reel/Frame 044495/0657 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2014
From: GANYMED PHARMACEUTICALS AG
To: BIONTECH AG
Reel/Frame 031956/0113 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2010
From: KOSLOWSKI, MICHAEL
To: GANYMED PHARMACEUTICALS AG
Reel/Frame 024352/0243 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2007
From: TURECI, OZLEM; SAHIN, UGUR; HELFTENBEIN, GERD; SCHNEIDER, SANDRA; SCHLUTER, VOLKER; USENER, DIRK; THIEL, PHILIPPE
To: GANYMED PHARMACEUTICALS AG
Reel/Frame 019523/0962 →
Priority Claims (1)
DE 10 2004 023 187 · May 11, 2004 · national
Continuity (1)
Related Publication 20080193454A1 · Aug 14, 2008